MedTrace Logo

Long-term Administration Study of SND 919 Tablets in Parkinson's Disease

NCT00274131 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2012-05-21

No results posted yet for this study

Summary

To evaluate the efficacy and safety of long-term treatment with pramipexole tablets (BI Sifrol®) in Parkinson's disease (phase III study).

Conditions

  • Parkinson Disease

Interventions

DRUG

Pramipexole 0.125 mg tablets

DRUG

Pramipexole 0.5 mg tablets

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim Study Coordinator · Nippon Boehringer Ingelheim Co., Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-12-31
Completion
2004-02-29

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00274131 on ClinicalTrials.gov